INFEKCIJA UZROKOVANA BAKTERIJOM CLOSTRIDIUM DIFFICILE (CD)

Todorović Z Dušan

doi:10.5937/mckg49-7660

Todorović Z Dušan Klinika za oftalmologiju KC Kragujevac u Kragujevcu

DOI: https://doi.org/10.5937/mckg49-7660

Sažetak

Toksigeni sojevi Klostridijum dificile (CD) u najvećem broju slučajeva izazivaju oboljenja intestinalnog trakta kod hospitalizovanih bolesnika. Dugo se smatralo da Klostridijum dificile produkuje oba tipa toksina (A +/ B+ soj), međutim istraživanja sprovedena poslednjih desetak godina ukazuju na postojanje i klinički značajnih sojeva koji luče samo toksin B ,tj. toksin A su negativni .S obzirom da je dokazano da su toksikogeni sojevi izolovani i u našj zemlji, u diferencijalnoj etiološkoj dijagnozi dijarealnog sindroma mora se uzeti u razmatranje i ova vrsta bakterija.S obzirom da mogu izazavati teške oblike oboljenja, obavezno je utvrđivanje prisustva pojedinih toksina u uzorcima stolice bolesnika i / ili produkcija pojedinih toksina u tečnim kulturama izolata.

Reference

Dale N. Gerding, Stuart Johnson. Clostridium difficile–Associated Disease, Including Pseudomembranous Colitis.In:Fauci AS (ed).Harrison’s principles of internal medicine, 17th edition. McGraw Hill Medical: New York, USA, 2008, pp 818-21.

Cohen SH , Gerding DN , Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control and Hosp Epidemiol 2010; 31: 431– 55.

Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections. Am J Gastroenterol 2013; 108:478–498; doi: 10.1038/ajg.2013.4; published online 26 February 2013.

Janarthanan S , Ditah I , Phil M et al. Clostridium difficile -associated diarrhea and proton pump inhibitor therapy: a meta-analysis . Am J Gastroentrol 2012 ; 107 : 1001 – 10.

Kwok CS , Arthur AK , Anibueze CI et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis . Am J Gastroenterol 2012 ; 107 : 1011 – 9.

Rodemann JF , Dubberke ER , Reske KA et al. Incidence of Clostridium difficile infection in infl ammatory bowel disease . Clin Gastroenterol Hepatol 2007 ; 5 : 339 – 44.

Issa M , Ananthakrishnan AN , Binion DG . Clostridium difficile and inflammatory bowel disease . Infl am Bowel Dis 2008 ; 14 : 1432 – 42.

McFarland LV , Surawicz CM , Stamm WE . Risk factors for Clostridium difficile carriage and C. difficile -associated diarrhea in a cohort of hospitalized patients . J Infect Dis 1990 ; 162 : 678 – 84.

Al-Eidan FA , McElnay JC , Scott MG et al. Clostridium difficile –associated diarrhea in hospitalized patients . J Clin Pharm Th er 2000 ; 25 : 101 – 9.

Deshpande A , Pant C , Pasupuleti V et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a metaanalysis. Clin Gastroenterol Hepatol 2012 ; 10 : 225 – 33.

Vestcinsdottir I , Gudlaugsdottir S , Einarsdottir R et al. Risk factors for Clostridium difficile toxin-positive diarrhea: a population-based prospective case-control study. Eur J Clin Microbiol Infect Dis 2012. ePub.

Bavishi C , DuPont HL . Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection . Alimen Pharmacol Ther 2011 ; 34 : 1269 – 81.

Kyne L , Warny M , Qamar A e t al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A . N Engl J Med 2000 ; 342 : 390 – 7.

Loo VG , Poirier L , Miller MA et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile -associated diarrhea with high morbidity and mortality . N Engl J Med 2005 ; 353 : 2442 – 9.

Muto CA , Pokrywka M , Shutt K et al. A large outbreak of Clostridium difficile -associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fl uoroquinolone use. Infect Control Hosp Epidemiol 2005 ; 26 : 273 – 80.

Kundrapu S , Sunkesula VCK , Jury LA et al. Utility of perirectal swab specimens for diagnosis of Clostridium difficile infection . Clin Infect Dis. 2012 ; 55 : 1527 – 30.

Morgan OW et al. Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study . PLoS One 2008 ; 3 : 31813.

Cloud J , Noddin I , Pressman A e t al. Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting . Clin Gastroenterol Hepatol 2009 ; 7 : 868 – 73.

Sirard S , Valiquette L , Fortier L - C . Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulenceassociated phenotypes . J Clin Microbiol 2011; 49 :4040 – 6.

Goldenberg SD , French GI . Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile . J Infect 2011 ; 62 : 355 – 62.

Goorthuis A , Debast SB , van Leengoed LAMG et al. Clostridium difficile PCR Ribotype 078: an emerging strain in humans and in pigs? J Clin Microbiol 2008 ; 46 : 1157 – 8.

Arvand M , Hauri AM , Zaiss NH , Witte W , Bettge-Weller G . Clostridium difficile ribotyes 001, 017, and 027 are associated with lethal C . difficile infection in Hesse, Germany. Euro Surveill 2009 ; 14 : 19403.

Samore MH , Venkataraman L , DeGirolami PC et al. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med 1996 ; 100 : 32 – 40 .

Chang VT , Nelson K . Th e role of physical proximity in nosocomial diarrhea.Clin Infect Dis 2000 ; 31 : 717 – 22.

Cohen SH , Tang YJ , Rahmani D et al. Persistence of an endemic (toxigenic) isolate of Clostridium difficile in the environment of a general medicine warд.Clin Infect Dis 2000 ; 30 : 952 – 4.

Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1067–1079.

Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008; 46 (suppl 1): S12–S18.

Kuijper EJE, Coignard BB, T€ull PP. Emergence of Clostridiuм difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006; 12 (suppl 6): 2–18.

Crobach MJT, Goorhuis A, Kelly CP et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009; 15: 1053–1066.

Knoop FC, Owens M, Crocker IC. Clostridium difficile: clinical disease and diagnosis. Clin Microbiol Rev 1993; 6: 251–265.

Moudgal V, Sobel J. Clostridium difficile colitis: a review. Hosp Pract 2012; 40: 139–148.

Planche T , Wilcox M . Reference assays for Clostridium difficile infection: one or two gold standards? J Clin Pathol 2011 ; 64 : 1 – 5.

Sambol SP , Merrigan MM , Lyerly D et al. Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease . Infect Immun 2000 ; 68 : 5480 – 82.